Skip to main content
Home / Current Drug Targets, Volume 15, Number 14
Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will be devoted to a single timely topic, with series of in-depth reviews, written by leaders in the field, covering a range of current topics on drug targets. These issues will be organized and led by a guest editor who is a recognized expert in the overall topic. As the discovery, identification, characterisation and validation of novel human drug targets for drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.

Publisher: Bentham Science Publishers

More about this publication?
Volume 15, Number 14, 2014

Articles

Free Content Editorial: New Strategies and Applications for Drugs Targeting EGFR and c-Met
pp. 1261-1262(2)
Authors: Giovannetti, E.; Leon, L.G.

Favourites:
ADD

Clinical Pharmacology of EGFR/Met Inhibitors in Non-Small Cell Lung Cancer
pp. 1263-1272(10)
Authors: Yagishita, Shigehiro; Hamada, Akinobu

Favourites:
ADD

Epidermal Growth Factor Receptor Targeting in Non-Small Cell Lung Cancer: Revisiting Different Strategies Against the Same Target
pp. 1273-1283(11)
Authors: Castanon, Eduardo; Martin, Patricia; Rolfo, Christian; P. Fusco, Juan; Ceniceros, Lucia; Legaspi, Jairo; Santisteban, Marta; Gil-Bazo, Ignacio

Favourites:
ADD

The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFRInhibitors: Did We Really Find the Target?
pp. 1284-1292(9)
Authors: Passiglia, Francesco; Van Der Steen, Nele; Raez, Luis; Pauwels, Patrick; Gil-Bazo, Ignacio; Santos, Edgardo; Santini, Daniele; Tesoriere, Giovanni; Russo, Antonio; Bronte, Giuseppe; Zwaenepoel, Karen; Cappuzzo, Federico; Rolfo, Christian

Favourites:
ADD

EGFR as a Potential Target for the Treatment of Pancreatic Cancer: Dilemma and Controversies
pp. 1293-1301(9)
Authors: Nedaeinia, Reza; Avan, Amir; Manian, Mostafa; Salehi, Rasoul; Ghayour-Mobarhan, Majid

Favourites:
ADD

Targeting c-MET/HGF Signaling Pathway in Upper Gastrointestinal Cancers: Rationale and Progress
pp. 1302-1311(10)
Authors: Gholamin, Sharareh; Fiuji, Hamid; Maftouh, Mina; Mirhafez, Reza; Homaei Shandiz, Fatemeh; Avan, Amir

Favourites:
ADD

Modulation of Signaling Enhances the Efficacy of the Combination of Satraplatin and Erlotinib
pp. 1312-1321(10)
Authors: Avan, Abolfazl; D. Adema, Auke; K. Hoebe, Eveline; M. Huijts, Charlotte; Avan, Amir; J. Veal, Gareth; Ruijtenbeek, Rob; Wosikowski, Katja; J. Peters, Godefridus

Favourites:
ADD

The EGFR Pathway Regulates BCRP Expression in NSCLC Cells: Role of Erlotinib
pp. 1322-1330(9)
Authors: Porcelli, Letizia; Giovannetti, Elisa; G. Assaraf, Yehuda; Jansen, Gerrit; L. Scheffer, George; Kathman, Ietje; Azzariti, Amalia; Paradiso, Angelo; J. Peters, Godefridus

Favourites:
ADD

Synergistic Activity of the c-Met and Tubulin Inhibitor Tivantinib (ARQ197) with Pemetrexed in Mesothelioma Cells
pp. 1331-1340(10)
Authors: G. Leon, Leticia; Gemelli, Maria; Sciarrillo, Rocco; Avan, Amir; Funel, Niccola; Giovannetti, Elisa

Favourites:
ADD

The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy
pp. 1341-1353(13)
Authors: H. Tan, Fiona; L. Putoczki, Tracy; S. Stylli, Stanley; B. Luwor, Rodney

Favourites:
ADD

Free Content Acknowledgements to Reviewers:
pp. 1354-1355(2)

Favourites:
ADD

Share Content

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content